Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

NCT04401995 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Vidutolimod (CMP-001)
BIOLOGICAL: Nivolumab
OTHER: [18F]F-AraG PET/CT

Sponsor

Diwakar Davar

Collaborators

[object Object]
[object Object]